Effect of High-Flow Oxygen on Exercise Performance in COPD Patients. Randomized Trial
Konstantinos Bitos, Michaël Furian, Laura Mayer, Simon Schneider, Simone Buenzli, Maamed Mademilov, Ulan Sheraliev, Nuridin H. Marazhapov, Ainura Abdraeva, Shoira Aidaralieva, Aybermet Muratbekova, Talant Sooronbaev, Silvia Ulrich, Konrad E. Bloch
Abstract
Background: High-flow oxygen therapy (HFOT) provides oxygen-enriched, humidified, and heated air at high flow rates via nasal cannula. It could be an alternative to low-flow oxygen therapy (LFOT) which is commonly used by patients with chronic obstructive pulmonary disease (COPD) during exercise training. Research Question: We evaluated the hypothesis that HFOT improves exercise endurance in COPD patients compared to LFOT. Methods: Patients with stable COPD, FEV 1 40–80% predicted, resting pulse oximetry (SpO 2 ) ≥92%, performed two constant-load cycling exercise tests to exhaustion at 75% of maximal work rate on two different days, using LFOT (3 L/min) and HFOT (60 L/min, FiO 2 0.45) in randomized order according to a crossover design. Primary outcome was exercise endurance time, further outcomes were SpO 2 , breath rate and dyspnea. Results: In 79 randomized patients, mean ± SD age 58 ± 9 y, FEV 1 63 ± 9% predicted, GOLD grades 2-3, resting PaO 2 9.4 ± 1.0 kPa, intention-to-treat analysis revealed an endurance time of 688 ± 463 s with LFOT and 773 ± 471 s with HFOT, mean difference 85 s (95% CI: 7 to 164, P = 0.034), relative increase of 13% (95% CI: 1 to 28). At isotime, patients had lower respiratory rate and higher SpO 2 with HFOT. At end-exercise, SpO 2 was higher by 2% (95% CI: 2 to 2), and Borg CR10 dyspnea scores were lower by 0.8 points (95% CI: 0.3 to 1.2) compared to LFOT. Interpretation: In mildly hypoxemic patients with COPD, HFOT improved endurance time in association with higher arterial oxygen saturation, reduced respiratory rate and less dyspnea compared to LFOT. Therefore, HFOT is promising for enhancing exercise performance in COPD. Clinical Trial Registration: www.ClinicalTrials.gov , identifier: NCT03955770.